帕金森病个性化治疗的自适应脑深部电刺激算法（ADAPT-PD）临床试验的传感数据和方法。

Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial.

作者信息

Stanslaski Scott, Summers Rebekah L S, Tonder Lisa, Tan Ye, Case Michelle, Raike Robert S, Morelli Nathan, Herrington Todd M, Beudel Martijn, Ostrem Jill L, Little Simon, Almeida Leonardo, Ramirez-Zamora Adolfo, Fasano Alfonso, Hassell Travis, Mitchell Kyle T, Moro Elena, Gostkowski Michal, Sarangmat Nagaraja, Bronte-Stewart Helen

机构信息

Medtronic Neuromodulation, Medtronic, Minneapolis, Minnesota, USA.

Massachusetts General Hospital, Harvard Medical School, Boston, USA.

出版信息

NPJ Parkinsons Dis. 2024 Sep 17;10(1):174. doi: 10.1038/s41531-024-00772-5.

Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic Percept PC neurostimulator. During the enrollment and screening procedures, a LFP (8-30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.

自适应深部脑刺激（aDBS）是深部脑刺激（DBS）技术的一项新兴进展；然而，对于aDBS算法而言足够的局部场电位（LFP）信号率检测以及设置aDBS的方法尚未明确。在此，我们总结了与正在进行的帕金森病个性化治疗自适应DBS算法（ADAPT-PD）关键试验（NCT04547712）相关的传感数据和aDBS编程步骤。68名患者入组，其丘脑底核或苍白球内侧部DBS电极与美敦力Percept PC神经刺激器相连。在入组和筛查过程中，临床医生在84.8%的服药患者（65%为双侧信号）和92%的未服药患者（78%为双侧信号）中识别出LFP（8 - 30 Hz，≥1.2 µVp）控制信号。ADAPT-PD试验的传感数据表明，这些患者在服药和未服药状态下均存在较高的LFP信号，且大多数为双侧信号，与帕金森病表型无关。